Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1013

1.

Feasibility of combined screening for upper gastrointestinal adenocarcinoma risk by serology and Cytosponge testing: the SUGAR study.

Xu Y, Miremadi A, Link A, Malfertheiner P, Fitzgerald RC, Bornschein J.

J Clin Pathol. 2019 Jun 24. pii: jclinpath-2019-205700. doi: 10.1136/jclinpath-2019-205700. [Epub ahead of print]

2.

Analysis of Transcriptionally Active Bacteria Throughout the Gastrointestinal Tract of Healthy Individuals.

Vasapolli R, Schütte K, Schulz C, Vital M, Schomburg D, Pieper DH, Vilchez-Vargas R, Malfertheiner P.

Gastroenterology. 2019 Jun 5. pii: S0016-5085(19)40986-4. doi: 10.1053/j.gastro.2019.05.068. [Epub ahead of print]

PMID:
31175864
3.

Within-host evolution of Helicobacter pylori shaped by niche-specific adaptation, intragastric migrations and selective sweeps.

Ailloud F, Didelot X, Woltemate S, Pfaffinger G, Overmann J, Bader RC, Schulz C, Malfertheiner P, Suerbaum S.

Nat Commun. 2019 May 22;10(1):2273. doi: 10.1038/s41467-019-10050-1.

4.

Transcriptomic profiling reveals three molecular phenotypes of adenocarcinoma at the gastroesophageal junction.

Bornschein J, Wernisch L, Secrier M, Miremadi A, Perner J, MacRae S, O'Donovan M, Newton R, Menon S, Bower L, Eldridge MD, Devonshire G, Cheah C, Turkington R, Hardwick RH, Selgrad M, Venerito M, Malfertheiner P; OCCAMS Consortium, Fitzgerald RC.

Int J Cancer. 2019 May 3. doi: 10.1002/ijc.32384. [Epub ahead of print]

PMID:
31050820
5.

Reconciliation of Recent Helicobacter pylori Treatment Guidelines in a Time of Increasing Resistance to Antibiotics.

Fallone CA, Moss SF, Malfertheiner P.

Gastroenterology. 2019 Jul;157(1):44-53. doi: 10.1053/j.gastro.2019.04.011. Epub 2019 Apr 15. Review.

PMID:
30998990
6.

The Rationale and Efficacy of Primary and Secondary Prevention in Adenocarcinomas of the Upper Gastrointestinal Tract.

Bornschein J, Bird-Lieberman EL, Malfertheiner P.

Dig Dis. 2019;37(5):381-393. doi: 10.1159/000499706. Epub 2019 Apr 10. Review.

7.

TLR1 and PRKAA1 Gene Polymorphisms in the Development of Atrophic Gastritis and Gastric Cancer.

Dargiene G, Streleckiene G, Skieceviciene J, Leja M, Link A, Wex T, Kupcinskas L, Malfertheiner P, Kupcinskas J.

J Gastrointestin Liver Dis. 2018 Dec;27(4):363-369. doi: 10.15403/jgld.2014.1121.274.tlr.

8.

Combined Gastric and Colorectal Cancer Screening-A New Strategy.

Selgrad M, Bornschein J, Kandulski A, Weigt J, Roessner A, Wex T, Malfertheiner P.

Int J Mol Sci. 2018 Dec 3;19(12). pii: E3854. doi: 10.3390/ijms19123854.

9.

Radioablation by Image-Guided (HDR) Brachytherapy and Transarterial Chemoembolization in Hepatocellular Carcinoma: A Randomized Phase II Trial.

Mohnike K, Steffen IG, Seidensticker M, Hass P, Damm R, Peters N, Seidensticker R, Schütte K, Arend J, Bornschein J, Streitparth T, Wybranski C, Wieners G, Stübs P, Malfertheiner P, Pech M, Ricke J.

Cardiovasc Intervent Radiol. 2019 Feb;42(2):239-249. doi: 10.1007/s00270-018-2127-5. Epub 2018 Nov 28.

PMID:
30488303
10.

Long-Term Effect of Rifaximin with and without Lactulose on the Active Bacterial Assemblages in the Proximal Small Bowel and Faeces in Patients with Minimal Hepatic Encephalopathy.

Schulz C, Schütte K, Vilchez-Vargas R, Vasapolli R, Malfertheiner P.

Dig Dis. 2019;37(2):161-169. doi: 10.1159/000494216. Epub 2018 Nov 14.

PMID:
30428474
11.

[Gastrointestinal innovations].

Malfertheiner P, Mayerle J.

MMW Fortschr Med. 2018 Nov;160(Suppl 3):58-63. doi: 10.1007/s15006-018-1124-6. Review. German. No abstract available.

PMID:
30421194
12.

Helicobacter pylori Infection: New Facts in Clinical Management.

Malfertheiner P, Venerito M, Schulz C.

Curr Treat Options Gastroenterol. 2018 Dec;16(4):605-615. doi: 10.1007/s11938-018-0209-8. Review.

PMID:
30415359
13.

Food-Derived Xeno-microRNAs: Influence of Diet and Detectability in Gastrointestinal Tract-Proof-of-Principle Study.

Link J, Thon C, Schanze D, Steponaitiene R, Kupcinskas J, Zenker M, Canbay A, Malfertheiner P, Link A.

Mol Nutr Food Res. 2019 Jan;63(2):e1800076. doi: 10.1002/mnfr.201800076. Epub 2018 Nov 20.

PMID:
30378765
14.

OLGA Gastritis Staging for the Prediction of Gastric Cancer Risk: A Long-term Follow-up Study of 7436 Patients.

Rugge M, Genta RM, Fassan M, Valentini E, Coati I, Guzzinati S, Savarino E, Zorzi M, Farinati F, Malfertheiner P.

Am J Gastroenterol. 2018 Nov;113(11):1621-1628. doi: 10.1038/s41395-018-0353-8. Epub 2018 Oct 17.

PMID:
30333540
15.

Gastric cancer: epidemiology, prevention, and therapy.

Venerito M, Vasapolli R, Rokkas T, Malfertheiner P.

Helicobacter. 2018 Sep;23 Suppl 1:e12518. doi: 10.1111/hel.12518. Review.

PMID:
30203589
16.

Evidence for PTGER4, PSCA, and MBOAT7 as risk genes for gastric cancer on the genome and transcriptome level.

Heinrichs SKM, Hess T, Becker J, Hamann L, Vashist YK, Butterbach K, Schmidt T, Alakus H, Krasniuk I, Höblinger A, Lingohr P, Ludwig M, Hagel AF, Schildberg CW, Veits L, Gyvyte U, Weise K, Schüller V, Böhmer AC, Schröder J, Gehlen J, Kreuser N, Hofer S, Lang H, Lordick F, Malfertheiner P, Moehler M, Pech O, Vassos N, Rodermann E, Izbicki JR, Kruschewski M, Ott K, Schumann RR, Vieth M, Mangold E, Gasenko E, Kupcinskas L, Brenner H, Grimminger P, Bujanda L, Sopeña F, Espinel J, Thomson C, Pérez-Aísa Á, Campo R, Geijo F, Collette D, Bruns C, Messerle K, Gockel I, Nöthen MM, Lippert H, Ridwelski K, Lanas A, Keller G, Knapp M, Leja M, Kupcinskas J, García-González MA, Venerito M, Schumacher J.

Cancer Med. 2018 Oct;7(10):5057-5065. doi: 10.1002/cam4.1719. Epub 2018 Sep 6.

17.

Efficacy, immunogenicity, and safety of a parenteral vaccine against Helicobacter pylori in healthy volunteers challenged with a Cag-positive strain: a randomised, placebo-controlled phase 1/2 study.

Malfertheiner P, Selgrad M, Wex T, Romi B, Borgogni E, Spensieri F, Zedda L, Ruggiero P, Pancotto L, Censini S, Palla E, Kanesa-Thasan N, Scharschmidt B, Rappuoli R, Graham DY, Schiavetti F, Del Giudice G.

Lancet Gastroenterol Hepatol. 2018 Oct;3(10):698-707. doi: 10.1016/S2468-1253(18)30125-0. Epub 2018 Jul 2.

PMID:
30042064
18.

The Iceman's Last Meal Consisted of Fat, Wild Meat, and Cereals.

Maixner F, Turaev D, Cazenave-Gassiot A, Janko M, Krause-Kyora B, Hoopmann MR, Kusebauch U, Sartain M, Guerriero G, O'Sullivan N, Teasdale M, Cipollini G, Paladin A, Mattiangeli V, Samadelli M, Tecchiati U, Putzer A, Palazoglu M, Meissen J, Lösch S, Rausch P, Baines JF, Kim BJ, An HJ, Gostner P, Egarter-Vigl E, Malfertheiner P, Keller A, Stark RW, Wenk M, Bishop D, Bradley DG, Fiehn O, Engstrand L, Moritz RL, Doble P, Franke A, Nebel A, Oeggl K, Rattei T, Grimm R, Zink A.

Curr Biol. 2018 Jul 23;28(14):2348-2355.e9. doi: 10.1016/j.cub.2018.05.067. Epub 2018 Jul 12.

19.

Helicobacter Pylori Infection.

Fischbach W, Malfertheiner P.

Dtsch Arztebl Int. 2018 Jun 22;115(25):429-436. doi: 10.3238/arztebl.2018.0429.

20.

Corrigendum to 'Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study' [Eur J Canc 81 (2017) 17-25].

Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JF, Park JO, Ryoo BY, Yen CJ, Kudo M, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Okusaka T, Bowman L, Cui ZL, Girvan AC, Abada PB, Yang L, Zhu AX.

Eur J Cancer. 2018 Sep;100:135-136. doi: 10.1016/j.ejca.2018.06.002. Epub 2018 Jun 30. No abstract available.

PMID:
29970352
21.

Helicobacter pylori eradication therapy is not associated with the onset of inflammatory bowel diseases. A case-control study.

Rosania R, Von Arnim U, Link A, Rajilic-Stojanovic M, Franck C, Canbay A, Malfertheiner P, Venerito M.

J Gastrointestin Liver Dis. 2018 Jun;27(2):119-125. doi: 10.15403/jgld.2014.1121.272.hpy.

22.

Expression of zinc transporters ZIP4, ZIP14 and ZnT9 in hepatic carcinogenesis-An immunohistochemical study.

Gartmann L, Wex T, Grüngreiff K, Reinhold D, Kalinski T, Malfertheiner P, Schütte K.

J Trace Elem Med Biol. 2018 Sep;49:35-42. doi: 10.1016/j.jtemb.2018.04.034. Epub 2018 Apr 27.

PMID:
29895370
23.

Nonerosive reflux disease: clinical concepts.

Gyawali CP, Azagury DE, Chan WW, Chandramohan SM, Clarke JO, de Bortoli N, Figueredo E, Fox M, Jodorkovsky D, Lazarescu A, Malfertheiner P, Martinek J, Murayama KM, Penagini R, Savarino E, Shetler KP, Stein E, Tatum RP, Wu J.

Ann N Y Acad Sci. 2018 Dec;1434(1):290-303. doi: 10.1111/nyas.13845. Epub 2018 May 15. Review.

PMID:
29761528
24.

Combined Systemic Chemotherapy and CT-Guided High-Dose-Rate Brachytherapy for Isolated Local Manifestation of Pancreatic Cancer after Surgical Resection.

Franck C, Hass P, Malfertheiner P, Ricke J, Seidensticker M, Venerito M.

Digestion. 2018;98(2):69-74. doi: 10.1159/000487359. Epub 2018 Apr 26.

PMID:
29698952
25.
26.

Circulating and Fecal microRNAs as Biomarkers for Inflammatory Bowel Diseases.

Schönauen K, Le N, von Arnim U, Schulz C, Malfertheiner P, Link A.

Inflamm Bowel Dis. 2018 Jun 8;24(7):1547-1557. doi: 10.1093/ibd/izy046.

PMID:
29668922
27.

Contribution of Helicobacter pylori infection to the risk of peptic ulcer bleeding in patients on nonsteroidal anti-inflammatory drugs, antiplatelet agents, anticoagulants, corticosteroids and selective serotonin reuptake inhibitors.

Venerito M, Schneider C, Costanzo R, Breja R, Röhl FW, Malfertheiner P.

Aliment Pharmacol Ther. 2018 Jun;47(11):1464-1471. doi: 10.1111/apt.14652. Epub 2018 Apr 14.

PMID:
29655196
28.

Helicobacter pylori Treatment for Gastric Cancer Prevention.

Malfertheiner P.

N Engl J Med. 2018 Mar 22;378(12):1154-1156. doi: 10.1056/NEJMe1800147. No abstract available.

PMID:
29562150
29.

Helicobacter Pylori Serology in Relation to Hepatitis C Virus Infection and IL28B Single Nucleotide Polymorphism.

Gutwerk A, Wex T, Stein K, Langner C, Canbay A, Malfertheiner P, Link A.

J Clin Med. 2018 Mar 5;7(3). pii: E44. doi: 10.3390/jcm7030044.

30.

Severe intestinal malabsorption associated with ACE inhibitor or angiotensin receptor blocker treatment. An observational cohort study in Germany and Italy.

Malfertheiner P, Ripellino C, Cataldo N.

Pharmacoepidemiol Drug Saf. 2018 Jun;27(6):581-586. doi: 10.1002/pds.4402. Epub 2018 Feb 19.

31.

STW 5 (Iberogast) Therapy in Gastrointestinal Functional Disorders.

Malfertheiner P.

Dig Dis. 2017;35 Suppl 1:25-29. doi: 10.1159/000485410. Epub 2018 Feb 8. Review.

32.

Functional Gastrointestinal Disorders: Complex Treatments for Complex Pathophysiological Mechanisms.

Mearin F, Malfertheiner P.

Dig Dis. 2017;35 Suppl 1:1-4. doi: 10.1159/000485407. Epub 2018 Feb 8. No abstract available.

33.

Expression of microRNAs in the ascites of patients with peritoneal carcinomatosis and peritonitis.

Schindler P, Kupcinskas J, Juzenas S, Skieceviciene J, Salteniene V, Schulz C, Weigt J, Malfertheiner P, Link A.

Cancer Cytopathol. 2018 May;126(5):353-363. doi: 10.1002/cncy.21966. Epub 2018 Jan 23.

34.

Neoadjuvant treatment with cisplatin and S-1 in elderly patients with oesophagogastric adenocarcinoma and locoregional disease: Two case reports and review of the literature.

Franck C, Canbay A, Malfertheiner P, Venerito M.

Mol Clin Oncol. 2017 Dec;7(6):1069-1072. doi: 10.3892/mco.2017.1445. Epub 2017 Oct 6.

35.

Genome-Wide Analysis of Barrett's Adenocarcinoma. A First Step Towards Identifying Patients at Risk and Developing Therapeutic Paths.

Dai Y, Wang Q, Gonzalez Lopez A, Anders M, Malfertheiner P, Vieth M, Kemmner W.

Transl Oncol. 2018 Feb;11(1):116-124. doi: 10.1016/j.tranon.2017.10.003. Epub 2017 Dec 18.

36.

Recurrent diffuse gastric bleeding as a leading symptom of gastrointestinal AL amyloidosis.

Franck C, Venerito M, Weigt J, Roessner A, Malfertheiner P.

Z Gastroenterol. 2017 Dec;55(12):1318-1322. doi: 10.1055/s-0043-120924. Epub 2017 Dec 6.

PMID:
29212103
37.

Validation of Hepa-index as a non-invasive biomarkers panel for assessment of hepatic fibrosis in Egyptians with chronic hepatitis C.

Alboraie M, Schütte K, Khairy M, Elsharkawy M, Asem N, Elghamry F, Shalaby H, Esmat G, Malfertheiner P.

Saudi Med J. 2017 Nov;38(11):1137-1142. doi: 10.15537/smj.2017.11.21220.

38.

Editorial: the non-invasive diagnosis of atrophic gastritis.

Malfertheiner P.

Aliment Pharmacol Ther. 2017 Dec;46(11-12):1112-1113. doi: 10.1111/apt.14340. No abstract available.

39.

Genome and Methylome Variation in Helicobacter pylori With a cag Pathogenicity Island During Early Stages of Human Infection.

Nell S, Estibariz I, Krebes J, Bunk B, Graham DY, Overmann J, Song Y, Spröer C, Yang I, Wex T, Korlach J, Malfertheiner P, Suerbaum S.

Gastroenterology. 2018 Feb;154(3):612-623.e7. doi: 10.1053/j.gastro.2017.10.014. Epub 2017 Oct 21.

PMID:
29066327
40.

Influence of laboratory-related and endoscopy-related factors on the assessment of serum pepsinogens and gastrin-17.

Goni E, Venerito M, Schulz C, Weigt J, Langner C, Link A, Malfertheiner P.

Eur J Gastroenterol Hepatol. 2017 Dec;29(12):1340-1345. doi: 10.1097/MEG.0000000000000952.

PMID:
28984679
41.

Modified Helicobacter test using a new test meal and a 13C-urea breath test in Helicobacter pylori positive and negative dyspepsia patients on proton pump inhibitors.

Tepeš B, Malfertheiner P, Labenz J, Aygen S.

World J Gastroenterol. 2017 Aug 28;23(32):5954-5961. doi: 10.3748/wjg.v23.i32.5954.

42.

Proton-pump inhibitors: understanding the complications and risks.

Malfertheiner P, Kandulski A, Venerito M.

Nat Rev Gastroenterol Hepatol. 2017 Dec;14(12):697-710. doi: 10.1038/nrgastro.2017.117. Epub 2017 Sep 20. Review.

PMID:
28930292
43.

Helicobacter pylori, gastric cancer and other gastrointestinal malignancies.

Venerito M, Vasapolli R, Rokkas T, Delchier JC, Malfertheiner P.

Helicobacter. 2017 Sep;22 Suppl 1. doi: 10.1111/hel.12413. Review.

PMID:
28891127
44.

Management of Helicobacter pylori Infection: What Should the Surgeon Know?

Selgrad M, Malfertheiner P.

Visc Med. 2017 Jun;33(3):216-219. doi: 10.1159/000477977. Epub 2017 Jun 16. Review.

45.

Helicobacter pylori vacA genotype is a predominant determinant of immune response to Helicobacter pylori CagA.

Link A, Langner C, Schirrmeister W, Habendorf W, Weigt J, Venerito M, Tammer I, Schlüter D, Schlaermann P, Meyer TF, Wex T, Malfertheiner P.

World J Gastroenterol. 2017 Jul 14;23(26):4712-4723. doi: 10.3748/wjg.v23.i26.4712.

46.

Impact of thoracic surgery on esophageal motor function-Evaluation by high resolution manometry.

Wäsche A, Kandulski A, Malfertheiner P, Riedel S, Zardo P, Hachenberg T, Schreiber J.

J Thorac Dis. 2017 Jun;9(6):1557-1564. doi: 10.21037/jtd.2017.05.43.

47.

The prevalence of gastric heterotopia of the proximal esophagus is underestimated, but preneoplasia is rare - correlation with Barrett's esophagus.

Peitz U, Vieth M, Evert M, Arand J, Roessner A, Malfertheiner P.

BMC Gastroenterol. 2017 Jul 12;17(1):87. doi: 10.1186/s12876-017-0644-3.

48.

Sorafenib in Patients with Hepatocellular Carcinoma-Results of the Observational INSIGHT Study.

Ganten TM, Stauber RE, Schott E, Malfertheiner P, Buder R, Galle PR, Göhler T, Walther M, Koschny R, Gerken G.

Clin Cancer Res. 2017 Oct 1;23(19):5720-5728. doi: 10.1158/1078-0432.CCR-16-0919. Epub 2017 Jul 11.

49.

Road Map fluoroscopy successfully guides endoscopic interventions in the esophagus.

Weigt J, Obst W, Kandulski A, Pech M, Canbay A, Malfertheiner P.

Endosc Int Open. 2017 Jul;5(7):E608-E612. doi: 10.1055/s-0043-111719. Epub 2017 Jul 5.

50.

LINE-1 hypomethylation is not a common event in preneoplastic stages of gastric carcinogenesis.

Kupcinskas J, Steponaitiene R, Langner C, Smailyte G, Skieceviciene J, Kupcinskas L, Malfertheiner P, Link A.

Sci Rep. 2017 Jul 6;7(1):4828. doi: 10.1038/s41598-017-05143-0.

Supplemental Content

Loading ...
Support Center